 dose/continuous infusion schedule fludarabine phosphate chronic lymphocytic leukemia dose/continuous infusion schedule fludarabine phosphate patients chronic lymphocytic leukemia CLL patients evidence active disease majority Rai stages patients assessable response partial response stable disease Thirteen responders Rai stages fludarabine therapy patients stage rates pretreatment stages III IV Patients final Rai II survival stages III IV Patients undergone splenectomy therapy likely Myelosuppression primary toxicity cumulative Severe leukopenia thrombocytopenia infrequent several deaths early cycles treatment Nonhematologic toxicity mild serious neurotoxicity Infections common minor major fatal episodes Fludarabine phosphate alternative dosing schedule effective refractory advanced CLL majority patients